References
- Murthy VH. Ending the Opioid Epidemic — A Call to Action. [cited 2016 Dec 7]. Available from: http://www.nejm.org/doi/full/10.1056/NEJMp1612578
- Hughes A, Williams MR, Lipari RN, et al. Prescription drug use and misuse in the United States: Results form the 2015 National Survey on Drug Use. NSDUH Data Review. [cited 2016 Dec 7] . Available from: http://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.htm#appa
- Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. The DAWN Report. Highlights of the 2011 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. [cited 2015 Dec 10]. Available from: http://archive.samhsa.gov/data/2k13/DAWN127/sr127-DAWN-highlights.htm
- Centers for Disease Control and Prevention. Division of Vital Statistics, Mortality Data. Number and age-adjusted rates of drug-poisoning deaths involving opioid analgesics and heroin: United States, 1999-2014. [cited 2016 Dec 7]. Available from: http://www.cdc.gov/nchs/data/health_policy/AADR_drug_poisoning_involving_OA_Heroin_US_2000-2014.pdf
- Gladden RM, Martinez P, Seth P. Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths - 27 states, 2013-2014. MMWR Morb Mortal Wkly Rep. 2016;65:837–843.
- United Nations Office on Drugs and Crime. The non-medical use of prescription drugs. Policy direction issues. [cited 2015 Dec 10] Available from: https://www.unodc.org/documents/drug-prevention-and-treatment/nonmedical-use-prescription-drugs.pdf.
- Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health [NSDUH series H-50, HHS publication no.SMA 15-4927]. [cited 2015 Dec 10]. Available from: http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf
- Smith SM, Dart RC, Katz NP, et al. Analgesic, anesthetic, and addiction clinical trials, translations, innovations, opportunities and networks (ACTTION) public-private partnership. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154:2287–2296.
- Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37:205–217.
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Abuse-deterrent opioids — evaluation and labeling. Guidance for Industry. [cited 2015 11 Dec]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
- Webster L, St Marie B, McCarberg B, et al. Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain. J Opioid Manag. 2011;7:235–245.
- Comer SD, Zacny JP, Dworkin RH, et al. Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain. 2012;153:2315–2324.
- Budman SH, Grimes Serrano JM, Butler SF. Can abuse deterrent formulations make a difference? expectation and speculation. Harm Reduct J. 2009;6:8.
- Coplan PM, Chilcoat HD, Butler SF, et al. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin Pharmacol Ther. 2016;100:275–286.
- The IMS, National Prescription Audit™ (NPA) database.
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. [cited 2016 Nov 2]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM236242.pdf
- Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9:444–459.
- Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156:569–576.
- Setnik B, Roland CL, Sommerville KW, et al. A multicenter, primary care-based, open-label study to identify behaviors related to prescription opioid misuse, abuse, and diversion in opioid-experienced patients with chronic moderate-to-severe pain. J Pain Res. 2015;8:361–373.
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee. [cited 2016 Nov 11]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM514378.pdf.
- US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2009 National Survey on Drug Use and Health: volume I. Summary of national findings [NSDUH series H-38A, HHS publication no. SMA 10-4856Findings]. [cited 2015 Dec 10]. Available from: http://archive.samhsa.gov/data/NSDUH/2k9NSDUH/2k9Results.htm
- Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004;23:1–9.
- Butler SF, Budman SH, Licari A, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17:1142–1154.
- Butler SF, Black RA, Cassidy TA, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8:29.
- Rosenblum A, Parrino M, Schnoll SH, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007;90:64–71.
- Katz N, Fernandez K, Chang A, et al. Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain. 2008;24:528–535.
- Passik SD, Hays L, Eisner N, et al. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20:5–13.
- Villapiano A, Butler S, Budman S, et al. Demonstration of the feasibility of real-time, product-specific, prescription opioid abuse surveillance: the NAVIPPRO system. Presented at: 68th Annual Scientific Meeting of the College on Problems of Drug Dependence; Jun 17–22, 2006; Scottsdale, AZ.
- White AG, Birnbaum HG, Rothman DB, et al. Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction. Appl Health Econ Health Policy. 2009;7:61–70.
- US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2008 National Survey on Drug Use and Health: national findings [NSDUH series H-36, HHS publication no. SMA 09-4434]. [cited 2015 Dec 11]. Available from: http://archive.samhsa.gov/data/NSDUH/2k8nsduh/2k8results.pdf
- Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372:241–248.
- Setnik B, Roland CL, Barsdorf AI, et al. Content validity of the SR-MAD Rx opioids instrument for use in patients with acute or chronic pain. Value Health. 2014;17:A220.
- Paulozzi LJ, Weisler RH, Patkar AA. A national epidemic of unintentional prescription opioid overdose deaths: how physicians can help control it. J Clin Psychiatry. 2011;72:589–592.
- Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23:648–660.